Survey of Pediatric Pain Management

No Pain
Mild Pain
Discomforting
Distressing
Intense
Excruciating
Now there are two CME in the SUN events in 2015 to choose from. Early Registration Deadline: September 15, 2014. Register at caep.ca/cme-sun

Iberostar Rose Hall
Jamaica
February 21-28, 2015

Beaches Resort
Turks & Caicos
January 24-31, 2015

CAPE TOWN, SOUTH AFRICA
*Voted the number-one City in the World to visit in 2014 by The New York Times & The Guardian

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 April 2015</td>
<td>Abstract Submission Opens</td>
</tr>
<tr>
<td>18 July 2015</td>
<td>Online Registration Opens</td>
</tr>
<tr>
<td>1 September 2015</td>
<td>Abstract Submission Closes</td>
</tr>
<tr>
<td>18 December 2015</td>
<td>Early Bird Registration Closes</td>
</tr>
<tr>
<td>1 April 2016</td>
<td>Online Registration Closes</td>
</tr>
</tbody>
</table>
Table of Contents • Table des matières

LETTERS • CORRESPONDANCE

343 Thyrotoxic Periodic Paralysis, $\beta_2$-Adrenergic Bronchodilator, and Insulin—An Interesting Interplay
Subramanian Senthilkumaran, Narendra Nath Jena, Srinivasan Jayaraman, Ponniah Thirumalaikolundusubramanian

344 In Reply to “Thyrotoxic Periodic Paralysis, $\beta_2$-Adrenergic Bronchodilator, and Insulin—An Interesting Interplay”
Chih-Jen Cheng, Shih-Hua Lin

ORIGINAL RESEARCH • RECHERCHE ORIGINALE

Education
345 Point-of-care ultrasonography adoption in Canada: using diffusion theory and the Evaluation Tool for Ultrasound skills Development and Education (ETUDE)
Michael Y. Woo, Jason R. Frank, A. Curtis Lee

Pediatric EM
352 Reported practice variation in pediatric pain management: a survey of Canadian pediatric emergency physicians
Samina Ali, Andrea Chambers, David W. Johnson, Amanda S. Newton, Ben Vandermeer, Janie Williamson, Sarah J. Curtis

EM Advances
361 Radiological errors in the Canadian Journal of Emergency Medicine
James D. McEachern, David A. Leswick, Grant W. Stoneham, Karen L. Mohr, James E. Stempien

EMS
370 Assessment of older adults by emergency medical services: methodology and feasibility of a care partner Comprehensive Geriatric Assessment (CP-CGA)
Judah Goldstein, Andrew Travers, Ruth Hubbard, Paige Moorhouse, Melissa K. Andrew, Kenneth Rockwood

EM Advances
378 Chest compressions do not disrupt the seal created by the laryngeal mask airway during positive pressure ventilation: a preliminary porcine study
Jestin N. Carlson, Brian P. Suffoletto, David D. Salcido, Eric S. Logue, James J. Menegazzi

About the Cover:
In this issue, a survey of Canadian Pediatric Emergency physicians reveals the practice variation in paediatric pain management in the emergency department.
Pediatric EM
383 Postresuscitation debriefing in the pediatric emergency department: a national needs assessment
Naminder Sandhu, Walter Eppich, Angelo Mikrogianakis, Vincent Grant, Traci Robinson, Adam Cheng

EM Advances
393 Familiarity with radiation exposure dose from diagnostic imaging for acute pulmonary embolism and current patterns of practice
Justin S. Ahn, Marcia L. Edmonds, Shelley L. McLeod, Jonathan F. Dreyer

Pediatric EM
405 Trends in use in a Canadian pediatric emergency department
Quynh Doan, Emerson D. Genuis, Alvis Yu

KNOWLEDGE TO PRACTICE • DES CONNAISSANCES À LA PRATIQUE

Diagnostic Challenge
411 Diaphragmatic hernia: an unexpected cause of pseudopleural effusion
Eeling Goh

Images
413 White cerebellum sign: red flag in the emergency department
Divya Singh, Amit Sharma

EDUCATION • ENSEIGNEMENT

414 Preparedness of urban, general emergency department staff for neonatal resuscitation in a Canadian setting
Nicole Kester-Greene, Jacques S. Lee

CASE REPORT • RAPPORT DE CAS

421 Drug-induced aseptic meningitis secondary to trimethoprim/sulfamethoxazole: a headache to be aware of
Joel R. Lockwood, David Carr

425 Anti-N-methyl-\(\text{d}\)-aspartate receptor (anti-NMDAR) encephalitis presenting to the emergency department with status epilepticus
Brodie Nolan, Katharina Plenk, David Carr

ADVERTISERS’ INDEX
INDEX DES ANNONCEURS

Allerject
A6, A7
Brilinta
A4, A5
Canadian Association of Emergency Physicians
C2, A5, A8, A9, A10, C3
Novartis
C4
Ross Memorial Hospital
A10

CJEM • JCMU
Canadian Journal of Emergency Medicine
Journal canadien de la médecine d'urgence

EDITOR-IN-CHIEF / RÉDACTEUR EN CHIEF
James Ducharme, MD
McMaster University, Hamilton, Ont.

SENIOR ASSOCIATE EDITORS / RÉDACTEURS ADJOINTS
Riyad B. Abu-Laban, MD, MHSc
University of British Columbia, Vancouver, BC
Eddy Lang, MD, CM
University of Calgary, Calgary, Alberta
Laurie J. Morrison, MD, MSc
University of Toronto, Toronto, Ont.
Marco L.A. Sivitti, MD, MSc
Queen’s University, Kingston, Ont.

MANAGING EDITOR / RÉDACTRICE ADMINISTRATIVE
Andrea Schaffeler, BA, BJourn
Pickering, Ont.

ASSISTANT MANAGING EDITOR / ADJOINTE À LA RÉDACTRICE ADMINISTRATIVE
Jennifer D. Arz, PhD

EDITOR EMERITUS / RÉDACTEUR ÉMÉRITE
Grant Innes, MD
University of Calgary, Calgary, Alta.

ASSOCIATE EDITORS / RÉDACTEURS ASSOCIÉS

EM ADVANCES
Jacques S. Lee, MD, University of Toronto, Toronto, Ont.
Heather Murray, MD, MSc, Queen’s University, Kingston, Ont.
Ian G. Steill, MD, MSc, University of Ottawa, Ottawa, Ont.

CJEM JOURNAL CLUB
Jo-Ann Talbot, MD, Dalhousie University, Saint John, NB.

COMMUNITY EM
David Mann, MD, Powell River General Hospital, Powell River, BC.

DIAGNOSTIC CHALLENGE
Brian Steinhardt, MD, St. Michael’s Hospital, Toronto, Ont.

ED ADMINISTRATION
Christopher M.B. Fernandes, MD, University of Western Ontario, London, Ont.

EDITORIALS/RADICAL DEPARTURE
Jeffrey Freeman, MD, University of Michigan, Ann Arbor, Mich.

EDUCATION
Jonathan Sherbino, MD, MEd, St. Joseph’s Hospital, Hamilton, Ont.

HUMOUR AND HUMANITY
Jeffrey Freeman, MD, University of Michigan, Ann Arbor, Mich.

INTERNATIONAL EM
Garth Dickinson, MD, University of Ottawa, Ottawa, Ont.

METHODOLOGY: THE SCIENCE OF EM
Editor:
Andrew Worster, MD, MSc, McMaster University, Hamilton, Ont.

REVIEWS:
Andrew G. Day, MSc, Queen’s University, Kingston, Ont.
Rob Steinstrom, MD, PhD, University of British Columbia, Vancouver, BC.
Garth Hunte, MD, PhD, University of British Columbia, Vancouver, BC.

PEDIATRIC EM
Run Goldman, MD, University of British Columbia, Vancouver, BC
Niranjan Kissoon, MD, University of British Columbia, Vancouver, BC

PHARMACOTHERAPY
Peter J. Zed, BSc(Pharm), PharmD, University of British Columbia, Vancouver, BC.
Jeff Epstein, MD, Kelowna General Hospital, Kelowna, BC

RESIDENT ISSUES EDITOR
Rohit Mohindra, MSc, MD, McGill University, Montreal, QC

STATE OF THE ART
Steven Brooks, MD, MHSc, Queen’s University, Kingston, Ont.

TOXICOLOGY
Roy Purssell, MD, University of British Columbia, Vancouver, BC

EDITORS AT LARGE / RÉDACTEURS OCCASIONNELS
Paul Atkinson, MB BCh BAO, MA, Dalhousie University & Saint John Regional Hospital, Saint John, NB
Alix Carter, MD, MPH, Dalhousie University, Halifax, NS
Jim Christenson, MD, University of British Columbia, Vancouver, BC
Stephen Choi, MD, The Ottawa Hospital, Ottawa, Ont.
Robert S. Green, MD, Dalhousie University, Halifax, NS
James Maskalyk, MD, St. Michael’s Hospital, Toronto, Ont.
Andrew McRae, MD, PhD, University of Calgary, Calgary, Alberta
Jeffrey Perry, MD, MSc, University of Ottawa, Ottawa, Ont.
Michael J. Schull, MD, MSc, Toronto, Ont.
Andrew H. Travers, BSc, MD, MSc (Epidemiol), Halifax, NS
Sunee Upadhye, MD, Hamilton, Ont.

TRANSLATION / TRANSLATION
Les Traductions Corpus

EDITORIAL INQUIRIES
Send to CJEM, c/o Andrea Schaffeler, Managing Editor, Canadian Journal of Emergency Medicine, 628 Cowan Circle, Pickering ON L1W 3K7; cjem@rogers.com

SUBMISSIONS
Submissions to CJEM should be made at http://mc.manuscriptcentral.com/cjem

SUBSCRIPTIONS AND ALL OTHER CORRESPONDENCE
CJEM is owned by the Canadian Association of Emergency Physicians (CAEP) and printed by General Printers, on acid-free stock.
CAEP Head Office: 180 Elgin Street, Suite 808, Ottawa, ON K2P 2K3; tel 613 523-3343; fax 613 523-0190; admin@caep.ca
Address changes: contact customerservice@deckerpublishing.com. Requests for permission to reproduce items in CJEM: contact permissions@deckerpublishing.com

CJEM represents the opinions of the authors and not necessarily those of CAEP, the publisher, its subsidiaries and their respective directors.

JOURNALS MANAGER
Paula Mucci

ADVERTISING / ANNONCES
John D. Birkby
jbirkby@andrewjohnpublishing.com

CJEM • JCMU

Decker
BRILINTA® IS COVERED ON PROVINCIAL FORMULARIES ACROSS CANADA

BRILINTA (ticagrelor), co-administered with acetylsalicylic acid (ASA), is indicated for the secondary prevention of atherothrombotic events in patients with Acute Coronary Syndromes (ACS) (unstable angina [UA], non-ST elevation myocardial infarction [NSTEMI] or ST elevation myocardial infarction [STEMI]) who are to be managed medically, and those who are to be managed with percutaneous coronary intervention (PCI) (with or without stent) and/or coronary artery bypass graft (CABG).

Formulary coverage for BRILINTA is offered in:
* British Columbia
* Alberta
* Saskatchewan
* Manitoba
* Ontario
* Quebec
* New Brunswick
* Nova Scotia
* Newfoundland and Labrador

Listed under Limited Coverage, Restricted Benefit or Special Authorization, Exception Drug Status, Exception Drug Status, Limited Use, Exception Drug, Special Authorization, Exception Status Drug and Special Authorization, respectively.1–9

Ticagrelor is recommended by the Canadian Cardiovascular Society in the 2012 Guidelines for the Use of Antiplatelet Therapy10†

• NSTEACS: In moderate to high risk NSTEACS patients managed with either PCI, CABG or medical therapy alone, ticagrelor + ASA is recommended for secondary prevention
• STEMI: In STEMI patients after primary PCI, ticagrelor + ASA is recommended for secondary prevention

NSTEACS: non-ST-segment elevation ACS
†See full guidelines for further information. ††See full guidelines for complete recommendations.
Clinical use:
Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacy of BRILINTA compared to clopidogrel, BRILINTA is recommended to be co-administered with low maintenance dose ASA (75-150 mg daily). The safety and efficacy of BRILINTA in pediatric patients below the age of 18 have not been established. Therefore, BRILINTA is not recommended in this population.

Contraindications:
• Patients with active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage)
• Patients with a history of intracranial hemorrhage
• Patients with moderate to severe hepatic impairment
• Patients who are also taking strong CYP3A4 inhibitors

Most serious warnings and precautions:
Bleeding risk: BRILINTA should be used with caution in patients with a propensity to bleed (e.g., due to recent trauma, recent surgery, active or recent gastrointestinal bleeding, or moderate hepatic impairment) and in patients requiring oral anticoagulants (e.g., warfarin) and/or fibrinolytics agents (within 24 hours of BRILINTA dosing). Caution should also be used in patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g., non-steroidal anti-inflammatory drugs [NSAIDs]).

Maintenance dose ASA: Co-administration of BRILINTA and high maintenance dose ASA (>150 mg daily) is not recommended.

Other relevant warnings and precautions:
• Cardiac events in discontinuous patients
• Bradycardic events
• Hypersensitivity, including angioedema
• Dizziness and confusion
• Discontinuation prior to surgery
• Dyspnea
• Pregnant or nursing women
• Possible increase in creatinine levels
• Uric acid increase

For more information:
Consult the Product Monograph at azinfo.ca/brilinta/pm274 for important information regarding adverse reactions, drug interactions and dosing information not discussed in this piece. The Product Monograph is also available by calling AstraZeneca Canada at 1-800-668-6000.15

References:
10. Canadian Cardiovascular Society. 2012 Focused Update on Antithrombotic agents (Within 24 hours of BRILINTA dosing). Caution should also be used in patients with concomitant administration of medicinal products that may increase the risk of bleeding. (e.g., non-steroidal anti-inflammatory drugs [NSAIDs]).

For more information:
Consult the Product Monograph at azinfo.ca/brilinta/pm274 for important information regarding adverse reactions, drug interactions and dosing information not discussed in this piece. The Product Monograph is also available by calling AstraZeneca Canada at 1-800-668-6000.15

Roadshow:
AIME Airway Intervention & Management in Emergencies
September 5, 2014 - Truro NS (SOLD OUT)
September 6, 2014 - Truro NS (SOLD OUT)
September 25, 2014 - Whistler BC (SOLD OUT)
October 6, 2014 - Vernon BC
November 12, 2014 - Quebec City QC*
November 13, 2014 - Quebec City QC*
December 10, 2014 - Montreal QC
December 11, 2014 - Montreal QC
February 18, 2015 - Halifax NS
April 7, 2015 - Montreal QC
April 8, 2015 - Montreal QC

EDTU: Emergency Department Targeted Ultrasound (Now 2 Day Course, Updated Curriculum)
November 1 & 2, 2014 - Toronto ON (SOLD OUT)
November 1 & 2, 2014 - Vancouver BC
December 6 & 7, 2014 - Montreal QC

RB: Risky Business - Clinical Decision Making in Emergency Medicine
November 25, 2014 - Sudbury ON

ID: Infectious Disease Management in Emergency Medicine
October 16, 2014 - Regina SK

REGISTER NOW!

*In conjunction with a conference, registration through the respective conference, not via CAEP.ca. Contact CAEP for details.
A VOICE...
WHEN YOURS
CAN’T BE
THERE

(Aprroximate size)

Allerject™ epinephrine auto-injector:

**It Talks!** The first and only epinephrine injector with audio instructions*

**Easy-Use Design!** Allerject™ was designed to be easy to use

**Compact!** Fits in your palm…designed for portability

**Lights Up!** LED flashes when injection is complete

*Comparative clinical significance unknown.

Living with the risk of anaphylaxis...

We’ll talk you through it! Allerject™

For more information: 1-855-405-4321 / Consumer website: www.allerject.ca
Indications and clinical use

Allerject™ 0.3 mg (0.3 mL Epinephrine Injection, USP, 1:1000) and Allerject™ 0.15 mg (0.15 mL Epinephrine Injection, USP, 1:1000) are indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight.

Allerject™ is intended for immediate self-administration for the emergency treatment of severe allergic reactions (Type I). Following treatment of anaphylaxis, the patient must seek immediate medical attention.

Contraindications:
No absolute contraindications

Relevant warnings and precautions:
• Inject into the outer thigh
• Use of more than 2 sequential doses
• Use in patients with cardiogenic, traumatic, or hemorrhagic shock; cardiac dilation; cerebral arteriosclerosis; cardiac arrhythmias; coronary artery or organic heart disease; hypertension or hyperthyroidism
• Patients with organic brain damage or Parkinson's disease
• Patients with narrow-angle glaucoma
• Use in diabetic patients
• Patients with sulfite sensitivity
• Patients with concomitant asthma

For more information:
Please consult the Prescribing Information at: products.sanofi.ca/en/allerject.pdf for important information relating to adverse reactions, drug interactions and dosing information which has not been discussed in this piece.

The Prescribing Information is also available by calling us at: 1-800-265-7927.

Manufactured for sanofi-aventis Canada Inc., Laval, Quebec, Canada H7V 0A3
Call for 2014/15
CAEP Research Grant Competition

Research is important in all areas of emergency medicine. Physicians, fellows, and residents working in diverse academic, non-academic, community, and rural settings are encouraged to submit CAEP Research Grant proposals.

IMPORTANT RESEARCH GRANT PROPOSAL DATES
Electronic submission opens: Monday, September 15, 2014 at 09:00 Eastern
Electronic submission closes: Thursday, October 30, 2014 at 23:59 Eastern (no exceptions)
Notification: January 30, 2015

PREREQUISITES FOR SUBMITTING GRANT PROPOSALS
✓ The Principal Investigator (PI) and Supervisor (for Residents and Fellows only) must be current CAEP members at the time of application. Proposals will not be reviewed if CAEP membership cannot be verified.
✓ Only CAEP members can receive grant funds.
✓ The PI must be <8 years beyond postgraduate training.
✓ A letter of support from Resident’s/Fellow’s Supervisor (or Department Head) must be included with the proposal.

GRANT SUBMISSION PROCESS
• Complete submission instructions are posted on the 2015 CAEP Abstract Central and CAEP Research webpages. (http://caep2015researchcompetitions.abstractcentral.com and http://caep.ca/ResearchOverview)
• Proposals are limited to 15,000 characters for abstract, research in depth, timeline and impact sections.
• References, research data collection tool, budget, CV, and support letter are not included in the character count.

The electronic submission process includes the following sections:
• Structured Research Abstract
• Research In Depth
• Timeline and Impact
• References
• Research Data Collection Tool
• Detailed Budget and Justification
• Curriculum vitae (CV) of the Principal Investigator
• Accompanying Support Letter from the Responsible Supervisor or Department Head

GRANT PROPOSAL REVIEWS
Grants are peer reviewed by three CAEP Grant Reviewers using a standardized evaluation form. Reviewers are blinded to the author’s name and institutional affiliations. Reviewers will not evaluate grants from their own province, and conflict of interest declarations are provided to each reviewer. Reviewers consider:
• Relevancy to emergency medicine
• Methodological quality
• Originality of the topic and methodology
• Level of training
• Ability to complete the proposed study

GRANT FUNDING PROVISIONS
A CAEP Grant for an individual project will not exceed $5000. CAEP financial support cannot be a supplement to other funding sources or used for meeting registration, travel, or equipment purchases.